Novavax Inc vs TORM plc — how do they compare? Novavax Inc trades at $7.96 (market cap $1.30B), while TORM plc trades at $28.6 (market cap $3.01B). The key difference: TORM plc is far larger — about 2.3× Novavax Inc's market cap, and TORM plc pays a 9.59% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | TRMD | |
|---|---|---|
Market Cap | $1.30B | $3.01B |
Sector | Health | Technology |
52-Week High | $11.19 | $34.87 |
52-Week Low | $6.22 | $18.77 |
Enterprise Value | $879.40M | $3.89B |
Dividend Yield | — | 9.59% |
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $7.95, up 2.71% with a bullish technical signal despite negative profitability metrics. The company shows mixed fundamentals with strong revenue growth to $1.12B in 2025 but negative net income margins. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook while cutting expenses. Analyst sentiment remains positive with 74% buy ratings.
Investment outlook balances strong partnerships and pipeline potential against persistent cash burn and negative equity. The Sanofi collaboration and Matrix-M adjuvant platform offer growth catalysts, but operational losses and high debt levels present significant risks. Stock appears undervalued on some metrics but requires careful monitoring of cash flow sustainability.
TRMD trades at $29.49 with a neutral daily change. The stock shows strong fundamentals with a P/E of 8.57, net income margin of 24.41%, and ROE of 15.62%, though recent Q1 2026 EPS missed expectations. Technical indicators are bearish overall, with support at $28 and resistance at $30. Recent news highlights strong Q1 2026 results and a dividend of $0.70 per share.
The outlook is positive with 100% analyst buy ratings and robust cash flow, but risks include earnings volatility and market sentiment. The stock offers value through dividends and growth potential, yet investors should monitor earnings consistency and macroeconomic factors affecting the tanker market.
Trailing returns across standard periods
Latest headlines on both assets
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →